Breaking: Senate Approves New Federal Medical Centre For Kaduna—Healthcare Boost Incoming

Published

The Nigerian Senate has passed the Federal Medical Centre Act (Amendment) Bill, 2024 (SB. 355), paving the way for the establishment of a Federal Medical Centre in Kafanchan, Kaduna State.

The bill, initially presented to the Senate on February 21, 2024, was sponsored by Senator Sunday Marshall Katung, representing Kaduna South Senatorial District.

The legislation marks a major step forward in addressing long-standing healthcare deficiencies in the region. Senator Katung described the Senate’s approval as a “transformational breakthrough” for Southern Kaduna, an area long underserved by adequate medical facilities.

He emphasized that the new FMC will significantly ease the pressure of traveling long distances for specialized medical attention—a burden that has often led to delayed treatments and avoidable fatalities.

Although President Bola Ahmed Tinubu had previously approved the establishment of the centre, the formal legislative endorsement by both chambers of the National Assembly was necessary to complete the process. The bill will now move to a conference committee made up of members from both the Senate and the House of Representatives, after which it will be forwarded to the President for final assent.

Senator Katung noted that beyond improving access to healthcare, the centre is expected to serve as a catalyst for local economic growth—creating jobs, attracting medical professionals, and supporting research and medical training.

He extended appreciation to President Tinubu, Senate President Godswill Akpabio, Deputy Senate President Jibrin Barau, and his colleagues in the Senate for their support, stating:

“This is a meaningful step toward equitable federal healthcare access and reflects my commitment to real development in Southern Kaduna.”

The Senate’s passage of the bill is widely seen as a critical milestone toward the swift realization of the much-needed medical facility.

Author:
BushRadio

Comments

0 comments

    Join the discussion

    Use a display name or leave it blank to comment as Anonymous. Email is not required.